Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

TO THE EDITOR: In November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in South Africa.\(^1\) Since then, omicron has rapidly spread around the world. On November 26, 2021, the World Health Organization designated omicron as a variant of concern. The omicron variant was found to have at least 33 mutations (29 amino acid substitutions, 1 insertion of three amino acids, and 3 small deletions) in its spike (S) protein, as compared with early SARS-CoV-2 strains identified in Wuhan, China.\(^2\) Notably, 15 of the 29 substitutions were in the receptor-binding domain of the S protein, which is the primary target for monoclonal antibody–based therapy. This finding suggests that the monoclonal antibodies that have been approved by the Food and Drug Administration (FDA) may be less effective against the omicron variant.

We validated the reactivity of all seven monoclonal antibodies by means of enzyme-linked immunosorbent assay (ELISA) coated with recombinant S protein derived from the early Wuhan reference strain, as well as from representative alpha, beta, gamma, and delta variants. The results were consistent with published data\(^3\) (Table S2). These monoclonal antibodies neutralized the early strain (NC002) and the alpha (HP127) and delta (UW5250) variants with a low FRNT\(_{50}\) value (1.34 to 150.38 ng per milliliter), except for LY-CoV555 (marketed as bamlanivimab), which showed markedly higher FRNT\(_{50}\) values against the delta variant than against the early strain and the alpha variant (Table 1). This result was consistent with a previous study that showed an almost complete loss of activity for bamlanivimab against the delta variant, whereas LY-CoV016 (marketed as etesevimab), REGN10987 (marketed as imdevimab), and REGN10933 (marketed as casirivimab) inhibited this variant.\(^4\) Etesevimab did not neutralize the omicron (NC928), beta (HP01542), or gamma (TY7-503) variants even at the highest FRNT\(_{50}\) value (>50,000 ng per milliliter) that was tested. Bamlanivimab showed reduced neutralizing activity against the beta and gamma variants and did not neutralize omicron. Imdevimab had high neutralizing activity against the beta and gamma variants but lost activity against omicron. Casirivimab neutralized beta, gamma, and omicron with a high FRNT\(_{50}\) value (187.69 to 14,110.70 ng per milliliter); however, the FRNT\(_{50}\) value for omicron was higher by a factor of 18.6 than that for beta and higher by a factor of 75.2 than that for gamma. COV2-2196 (marketed as tixagevimab), COV2-2130 (marketed as cilgavimab), and S309 (precursor of drug marketed as sotrovimab) also retained neutralizing activity against beta, gamma, and omicron; however, the FRNT\(_{50}\) values of these monoclonal antibodies were higher by a factor of 3.7 to 198.2 for omicron than for beta or gamma.

All the combinations of monoclonal antibod-
## Table 1. Efficacy of Monoclonal Antibodies and Antiviral Drugs against SARS-CoV-2 Variants In Vitro.

<table>
<thead>
<tr>
<th>Monoclonal Antibody or Antiviral Drug</th>
<th>SARS-CoV-2 Variant</th>
<th>Neutralization activity of monoclonal antibody — ng/ml†</th>
<th>Viral susceptibility to drug — μM‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SARS-CoV-2/UT-NC002-1T/Human/2020/Tokyo (A)</td>
<td>SARS-CoV-2/UT-HP127-1NF/Human/2021/Tokyo (Alpha/B.1.1.7)</td>
<td>hCoV-19/USA/MD-HPO1542/2021 (Beta/B.1.351)</td>
</tr>
<tr>
<td>LY-CoV016, etesevimab</td>
<td>18.19±9.10</td>
<td>150.38±83.51</td>
<td>&gt;50,000</td>
</tr>
<tr>
<td>LY-CoV555, bamlanivimab</td>
<td>4.69±1.43</td>
<td>2.65±1.30</td>
<td>9554.88±926.53</td>
</tr>
<tr>
<td>REGN10987, imdevimab</td>
<td>3.05±0.93</td>
<td>1.87±1.60</td>
<td>2.17±1.30</td>
</tr>
<tr>
<td>REGN10933, casirivimab</td>
<td>2.79±1.87</td>
<td>2.74±1.84</td>
<td>757.13±287.91</td>
</tr>
<tr>
<td>COV2-2196, tixagevimab</td>
<td>1.92±0.28</td>
<td>1.34±0.67</td>
<td>18.98±1.42</td>
</tr>
<tr>
<td>COV2-2130, cilgavimab</td>
<td>7.70±2.20</td>
<td>3.60±1.62</td>
<td>10.03±3.05</td>
</tr>
<tr>
<td>S309, sotrovimab precursor</td>
<td>27.33±3.24</td>
<td>44.91±22.76</td>
<td>100.98±22.27</td>
</tr>
<tr>
<td>LY-CoV016 plus LY-CoV555</td>
<td>12.60±1.91</td>
<td>15.26±3.98</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>REGN10987 plus REGN10933</td>
<td>3.53±0.66</td>
<td>1.55±0.78</td>
<td>5.18±1.45</td>
</tr>
<tr>
<td>COV2-2196 plus COV2-2130</td>
<td>3.42±0.92</td>
<td>1.94±0.34</td>
<td>10.30±1.17</td>
</tr>
</tbody>
</table>

† Plus–minus values are means ±SD. The antibodies used in this work were produced in the authors’ laboratory and are not identical to the commercially available products. The viral variants of SARS-CoV-2 are listed according to the World Health Organization labels for the Pango lineage.

‡ The individual monoclonal antibodies were tested at a starting concentration of 50,000 ng per milliliter as a 50% focus reduction neutralization titer. The monoclonal antibody combinations were tested at a starting concentration of 10,000 ng per milliliter for each antibody.

§ In this category, the value is the 50% inhibitory concentration of the mean micromole value of triplicate reactions.

‖ GS-441524 is the active form of remdesivir, an RNA-dependent RNA polymerase inhibitor.

¶ EIDD-1931 is the active form of molnupiravir, an RNA-dependent RNA polymerase inhibitor.

‖‖ PF-00835231 is the active form of PF-07304814, a protease inhibitor.
ies that were tested (i.e., etesevimab plus bamlanivimab, imdevimab plus casirivimab, and tixagevimab plus cilgavimab) neutralized the early strain and the alpha and delta variants. The combination of etesevimab plus bamlanivimab showed remarkably reduced neutralizing activity against gamma and lost neutralizing activity against omicron and beta. The imdevimab–casirivimab combination retained activity against beta and gamma but lost inhibitory capability against omicron. The tixagevimab–cilgavimab combination inhibited beta, gamma, and omicron; however, the FRNT50 values of this combination were higher by a factor of 24.8 to 142.9 for omicron than for beta or gamma, respectively.

The omicron variant has mutations in both the RNA-dependent RNA polymerase (RdRp) and the main protease of SARS-CoV-2, which are targets for antiviral drugs such as RdRp inhibitors (remdesivir and molnupiravir) and the main protease inhibitor PF-07304814, which arouses concern regarding the decreased effectiveness of these drugs against omicron. Thus, we tested three different antiviral compounds (i.e., remdesivir, molnupiravir, and PF-07304814) for their efficacy against omicron. The in vitro 50% inhibitory concentration (IC50) values of each compound were determined against NC928, NC002, HP127, HP01542, TY7-503, and UWS5250. The susceptibilities of omicron to the three compounds were similar to those of the early strain (i.e., IC50 values for remdesivir, molnupiravir, and PF-07304814 that differed by factors of 1.2, 0.8, and 0.7, respectively) (Table 1). These results suggest that all three of these compounds may show efficacy for treating patients infected with the omicron variant.

The potential limitations of our study include the lack of clinical data on the efficacy of these monoclonal antibodies and antiviral drugs for the treatment of patients infected with omicron. Additional studies are needed to determine whether these antiviral therapies are indeed effective against infection with the omicron variant. Collectively, our findings show that therapeutic options may be available to combat the omicron variant of SARS-CoV-2; however, some therapeutic monoclonal antibodies may not be effective against this variant.

Emi Takashita, Ph.D.
National Institute of Infectious Diseases
Tokyo, Japan

Noriko Kinoshita, M.D.
National Center for Global Health and Medicine
Tokyo, Japan

Seiya Yamayoshi, D.V.M., Ph.D.
Yuko Sakai-Tagawa, Ph.D.
University of Tokyo
Tokyo, Japan

Seiichiro Fujisaki, Ph.D.
National Institute of Infectious Diseases
Tokyo, Japan

Mutsumi Ito, D.V.M.
Kiyoko Iwatsuki-Horimoto, D.V.M., Ph.D.
University of Tokyo
Tokyo, Japan

Shiho Chiba, Ph.D.
Peter Halfmann, Ph.D.
University of Wisconsin–Madison
Madison, WI

Hiroyuki Nagai, M.D.
Makoto Saito, M.D., D.Phil.
Eisuke Adachi, M.D., Ph.D.
University of Tokyo
Tokyo, Japan

David Sullivan, M.D.
Andrew Pekosz, Ph.D.
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD

Shinji Watanabe, D.V.M., Ph.D.
National Institute of Infectious Diseases
Tokyo, Japan

Kenji Maeda, M.D., Ph.D.
National Center for Global Health and Medicine
Tokyo, Japan

Masaki Imai, D.V.M., Ph.D.
Hiroshi Yotsuyanagi, M.D., Ph.D.
University of Tokyo
Tokyo, Japan

Hiroaki Mitsuya, M.D., Ph.D.
Norio Ohmagari, M.D., Ph.D.
National Center for Global Health and Medicine
Tokyo, Japan

Makoto Takeda, M.D., Ph.D.
Hideki Hasegawa, M.D., Ph.D.
National Institute of Infectious Diseases
Tokyo, Japan

Yoshihiro Kawaoka, D.V.M., Ph.D.
University of Tokyo
Tokyo, Japan

yoshihiro.kawaoka@wisc.edu

Drs. Takashita and Kinoshita contributed equally to this letter.

Supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C, to Dr. Kawaoka) and from the Center for Research on Influenza Pathogenesis and Transmission (5RN93021C00014, to Dr. Kawaoka), funded by the National Institutes of Allergy and Infectious Diseases, and by a Research Program on Emerging and Reemerging Infectious
Diseases (JP20fk0108412 and JP21fk0108615, to Dr. Kawaoka; JP21fk0108104, to Dr. Watanabe), a Project Promoting Support for Drug Discovery (JP20nk0101632, to Dr. Kawaoka), the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002, to Dr. Kawaoka) from the Japan Agency for Medical Research and Development, a Grant-in-Aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor, and Welfare, Japan (20HA2007, to Dr. Hasegawa), and by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, in collaboration with the Defense Health Agency (contract number W911QY2090012, to Dr. Sullivan).

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on January 26, 2022, at NEJM.org.


DOI: 10.1056/NEJMc2119407

Correspondence Copyright © 2022 Massachusetts Medical Society.